

# H-1152

**Catalog No: tcsc1536**



## Available Sizes

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

451462-58-1

**Formula:**

$C_{16}H_{21}N_3O_2S$

**Pathway:**

TGF-beta/Smad; Stem Cell/Wnt; Cell Cycle/DNA Damage

**Target:**

ROCK; ROCK; ROCK

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

319.42


## Product Description

H-1152 is a membrane-permeable and selective **ROCK** inhibitor, with a  $K_i$  value of 1.6 nM, and an  $IC_{50}$  value of 12 nM for **ROCK2**.

IC50 & Target: IC50: 12 nM (ROCK2)<sup>[1]</sup>

Ki: 1.6 nM (ROCK)<sup>[2]</sup>

**In Vitro:** H-1152 is an inhibitor of Rho-kinase, with an  $IC_{50}$  of 12 nM for ROCK2. H-1152 (H-1152P) also shows less inhibitory activities against CaMKII, PKG, AuroraA, PKA, Src, PKC, MLCK, Abl, EGFR, MKK4, GSK3 $\alpha$ , AMPK, and P38 $\alpha$ , with  $IC_{50}$ s of 0.180, 0.360, 0.745, 3.03, 3.06, 5.68, 28.3, 7.77, 50.0, 16.9, 60.7, 100, and 100  $\mu$ M, respectively<sup>[1]</sup>. H-1152 potently inhibits Rho kinase, with a  $K_i$  of 1.6 nM, and slightly suppresses PKA, PKC and MLCK, with  $K_i$ s of 0.63, 9.27, and 10.1  $\mu$ M, respectively. H-1152 (0.1-10  $\mu$ M) highly inhibits MARCKS phosphorylation, with an  $IC_{50}$  value of 2.5  $\mu$ M in LPA-treated cells, but shows no such obvious effects in PDBu-treated cells<sup>[2]</sup>. H-1152 (0.5-10  $\mu$ M) causes no decreased neuronal survival. H-1152 (1, 5 or 10  $\mu$ M) also exerts no alterations in the ratios of different neuronal morphologies. Furthermore, H-1152 (10  $\mu$ M) increases neurite length in both BMP4 and LIF cultures<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!